Timber Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Co.'s product candidates include: TMB-001, a topical formulation of isotretinoin using its IPEG™ delivery system for the treatment of moderate to severe subtypes of congenital ichthyosis, a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist, and in preclinical development as an applied formulation for the treatment of sclerotic skin diseases.